Imatinib provides a second example of serendipitious target discovery. ... The broad kinome profiling of clinically approved and investigational kinase inhibitors is likely to help identify such ...

Imatinib (Gleevec, Novartis, Basel, Switzerland), formerly referred to as STI571, is an inhibitor of specific protein tyrosine kinases that was targeted to the platelet-derived growth factor (PDGF ...

Vatalanib is active despite its narrow kinome interaction spectrum in patients diagnosed with imatinib-resistant GIST or with imatinib and sunitinib-resistant GIST.

Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alf ...

The FDA first approved imatinib (Gleevec, Novartis), a protein-tyrosine kinase inhibitor, in 2001 under the accelerated approval program for use in adult patients with chronic myelogenous leukemia ...

Imatinib has now been used by more than 100,000 patients worldwide, totaling more than 200,000 patient-years of exposure, she noted. Also, the CML patient population tends to be elderly, ...

Imatinib monotherapy produces a high response rate in Ph+ ALL, but the responses are transient with recurrence in months. 8–11 Daily oral imatinib (260-570 mg/m 2 /d) is well tolerated in children and ...

In this Viewpoint, the authors discuss how imatinib could provide a potent therapeutic option for a variety of autoimmune and inflammatory diseases, for which current therapies are insufficient.

Imatinib interruption should not be considered for patients with advanced gastrointestinal stromal tumor who do not have progressive disease, according to results of a randomized phase 3 trial ...

Imatinib acts on underlying cellular proliferative pathways associated with PAH and has the potential to be the first disease modifying therapy for PAH. Tenax intends to commence a phase 3 trial ...

Data analysis included 136 patients, 71 randomized to 6 years of imatinib. About a third of patients in the control arm had an estimated recurrence risk of 35-70% versus 44% in the study arm, and ...

Median time to imatinib resistance favored uninterrupted treatment after 1 year, after 3 years (66.2 vs 127.3 months; HR 0.35, 95% CI 0.17-0.72, ...